Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
$0.21
$0.21
$0.21
▼
$3.09
$2.55M0.91482,532 shsN/A
Galmed Pharmaceuticals Ltd. stock logo
EOCN
Galmed Pharmaceuticals
$2.54
+2.4%
$3.75
$2.05
▼
$12.32
$2.64M0.7142,831 shs5,892 shs
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
$2.00
-9.4%
$4.97
$1.92
▼
$119.00
$581K1.95106,897 shs7,585 shs
Vaccinex, Inc. stock logo
VCNX
Vaccinex
$1.00
$0.95
$0.31
▼
$1.50
$2.60M1.12,732 shs26 shs
The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
0.00%0.00%0.00%0.00%-83.53%
Galmed Pharmaceuticals Ltd. stock logo
EOCN
Galmed Pharmaceuticals
0.00%-9.49%-12.98%-39.62%-70.19%
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
0.00%-14.04%-31.48%-77.22%-97.93%
Vaccinex, Inc. stock logo
VCNX
Vaccinex
0.00%0.00%-0.54%+28.88%+43.16%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
$0.21
$0.21
$0.21
▼
$3.09
$2.55M0.91482,532 shsN/A
Galmed Pharmaceuticals Ltd. stock logo
EOCN
Galmed Pharmaceuticals
$2.54
+2.4%
$3.75
$2.05
▼
$12.32
$2.64M0.7142,831 shs5,892 shs
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
$2.00
-9.4%
$4.97
$1.92
▼
$119.00
$581K1.95106,897 shs7,585 shs
Vaccinex, Inc. stock logo
VCNX
Vaccinex
$1.00
$0.95
$0.31
▼
$1.50
$2.60M1.12,732 shs26 shs
The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
0.00%0.00%0.00%0.00%-83.53%
Galmed Pharmaceuticals Ltd. stock logo
EOCN
Galmed Pharmaceuticals
0.00%-9.49%-12.98%-39.62%-70.19%
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
0.00%-14.04%-31.48%-77.22%-97.93%
Vaccinex, Inc. stock logo
VCNX
Vaccinex
0.00%0.00%-0.54%+28.88%+43.16%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
1.00
SellN/AN/A
Galmed Pharmaceuticals Ltd. stock logo
EOCN
Galmed Pharmaceuticals
1.00
SellN/AN/A
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
1.00
SellN/AN/A
Vaccinex, Inc. stock logo
VCNX
Vaccinex
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest NXTS, VCNX, EOCN, and CASI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/15/2026
Galmed Pharmaceuticals Ltd. stock logo
EOCN
Galmed Pharmaceuticals
Reiterated RatingSell (E+)
10/13/2026
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
Reiterated RatingSell (E+)
(Data available from 11/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
$26.85M0.10N/AN/A$0.12 per share1.73
Galmed Pharmaceuticals Ltd. stock logo
EOCN
Galmed Pharmaceuticals
N/AN/AN/AN/A$23.04 per shareN/A
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
$210K2.76N/AN/A$198.49 per share0.01
Vaccinex, Inc. stock logo
VCNX
Vaccinex
$388K6.70N/AN/A($2.59) per share-0.39
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
-$39.26M-$3.01N/AN/AN/A-183.93%N/A-131.54%N/A
Galmed Pharmaceuticals Ltd. stock logo
EOCN
Galmed Pharmaceuticals
-$10.31M-$15.18N/AN/AN/AN/A-73.68%-60.88%11/25/2026 (Estimated)
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
-$4M-$96.07N/AN/AN/AN/A-304.79%-178.91%N/A
Vaccinex, Inc. stock logo
VCNX
Vaccinex
-$20.25M-$48.27N/AN/AN/AN/AN/A-383.58%11/16/2026 (Estimated)

Latest NXTS, VCNX, EOCN, and CASI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/25/2026N/A
Galmed Pharmaceuticals Ltd. stock logo
EOCN
Galmed Pharmaceuticals
-$3.12N/AN/AN/AN/AN/A
11/16/2026Q3 2026
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
N/A-$0.29N/A-$0.29N/AN/A
11/16/2026N/A
Vaccinex, Inc. stock logo
VCNX
Vaccinex
-$73.0380N/AN/AN/A$0.33 millionN/A
9/2/2026Q2 2026
Galmed Pharmaceuticals Ltd. stock logo
EOCN
Galmed Pharmaceuticals
-$3.12-$2.86+$0.26-$2.86N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
N/AN/AN/AN/AN/A
Galmed Pharmaceuticals Ltd. stock logo
EOCN
Galmed Pharmaceuticals
N/AN/AN/AN/AN/A
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
N/AN/AN/AN/AN/A
Vaccinex, Inc. stock logo
VCNX
Vaccinex
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
N/A
0.30
0.24
Galmed Pharmaceuticals Ltd. stock logo
EOCN
Galmed Pharmaceuticals
N/A
4.16
4.16
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
0.12
3.72
3.72
Vaccinex, Inc. stock logo
VCNX
Vaccinex
N/A
0.77
0.77

Institutional Ownership

CompanyInstitutional Ownership
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
22.23%
Galmed Pharmaceuticals Ltd. stock logo
EOCN
Galmed Pharmaceuticals
76.14%
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
61.24%
Vaccinex, Inc. stock logo
VCNX
Vaccinex
50.11%

Insider Ownership

CompanyInsider Ownership
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
21.24%
Galmed Pharmaceuticals Ltd. stock logo
EOCN
Galmed Pharmaceuticals
19.80%
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
6.52%
Vaccinex, Inc. stock logo
VCNX
Vaccinex
51.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
18012.30 million9.69 millionNo Data
Galmed Pharmaceuticals Ltd. stock logo
EOCN
Galmed Pharmaceuticals
201.04 million836,000Not Optionable
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
9290,000272,000N/A
Vaccinex, Inc. stock logo
VCNX
Vaccinex
252.60 million1.26 millionNo Data

Recent News About These Companies

Vaccinex (VCNX) Projected to Announce Quarterly Earnings on Monday
Vaccinex Reports 2025 Annual Financial Results
Vaccinex Inc.

New MarketBeat Followers Over Time

Media Sentiment Over Time

CASI Pharmaceuticals stock logo

CASI Pharmaceuticals NASDAQ:CASI

$0.21 0.00 (0.00%)
As of 11/6/2026

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.

Galmed Pharmaceuticals stock logo

Galmed Pharmaceuticals NASDAQ:EOCN

$2.54 +0.06 (+2.42%)
As of 01:46 PM Eastern

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.

Nexentis Technologies stock logo

Nexentis Technologies NASDAQ:NXTS

$2.00 -0.21 (-9.37%)
As of 02:59 PM Eastern
This is a fair market value price provided by Massive. Learn more.

N2OFF, Inc., an agri-food tech company, engages in the development and sale of eco-friendly green solutions for the food industry to enhance food safety and shelf life of fresh produce. Its products are based on proprietary blend of food acids combined with various oxidizing agent-based sanitizers and low concentrated fungicides for cleaning, sanitizing, and controlling pathogens on fresh produce that are safer for human consumption and extend their shelf life by reducing their decay. The company's products include SavePROTECT or PeroStar, a processing aid for post-harvest application that is added to fruit and vegetable wash water; and SF3HS and SF3H, a post-harvest cleaning and sanitizing solution to control plant and foodborne pathogens. It also offers SpuDefender for controlling post-harvest potato sprouts; and FreshProtect to control spoilage-creating microorganisms on post-harvest citrus fruit. The company was formerly known as Save Foods, Inc. and changed its name to N2OFF, Inc. in March 2024. N2OFF, Inc. was incorporated in 2009 and is headquartered in Hod HaSharon, Israel.

Vaccinex stock logo

Vaccinex NASDAQ:VCNX

$1.00 0.00 (0.00%)
As of 11/13/2026

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 study for treatment of Alzheimer's disease and has completed phase 2 study for treatment of Huntington's disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer, Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 study with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab completed phase 2 study for melanoma, and trastuzumab and DC vaccine in phase 2 study for breast cancer. The company has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; The Children's Hospital of Philadelphia; Emory University; Huntington Study Group; H. Lee Moffitt Cancer Center and Research Institute, Inc; Catalent Pharma Solutions, LLC; Surface Oncology, Inc.; and Pharmaceutical and Biotech Co. The company was incorporated in 2001 and is headquartered in Rochester, New York.